8,680 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Fort L.P.

Fort L.P. acquired a new position in Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,680 shares of the biotechnology company’s stock, valued at approximately $225,000.

Several other large investors also recently added to or reduced their stakes in EXEL. First Trust Direct Indexing L.P. purchased a new position in Exelixis during the 1st quarter valued at about $250,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Exelixis by 3.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,771 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 1,301 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in Exelixis by 6.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 60,746 shares of the biotechnology company’s stock valued at $1,442,000 after buying an additional 3,510 shares in the last quarter. Nordea Investment Management AB grew its holdings in Exelixis by 17.3% during the 1st quarter. Nordea Investment Management AB now owns 202,292 shares of the biotechnology company’s stock valued at $4,835,000 after buying an additional 29,784 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Exelixis during the 1st quarter valued at about $1,281,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other news, EVP Dana Aftab sold 1,162 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Dana Aftab sold 1,162 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at $15,666,873. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $28.39, for a total value of $709,750.00. Following the transaction, the executive vice president now directly owns 580,325 shares in the company, valued at approximately $16,475,426.75. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 354,020 shares of company stock valued at $9,386,366. Insiders own 2.85% of the company’s stock.

Exelixis Price Performance

EXEL stock traded up $0.92 during midday trading on Friday, hitting $34.12. The stock had a trading volume of 4,537,149 shares, compared to its average volume of 2,454,909. The firm has a market cap of $9.74 billion, a price-to-earnings ratio of 21.87, a price-to-earnings-growth ratio of 0.89 and a beta of 0.51. The business has a 50-day moving average of $27.13 and a two-hundred day moving average of $24.29. Exelixis, Inc. has a 52-week low of $19.20 and a 52-week high of $34.45.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the prior year, the firm posted $0.10 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. Research analysts predict that Exelixis, Inc. will post 1.59 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on EXEL. Morgan Stanley lifted their target price on Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, October 11th. BMO Capital Markets boosted their price objective on Exelixis from $29.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday. UBS Group started coverage on Exelixis in a report on Thursday, September 19th. They set a “neutral” rating and a $30.00 price objective for the company. Bank of America boosted their price objective on Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. Finally, TD Cowen boosted their price objective on Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.44.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.